CoreStock

Stock price

Market cap

At each fiscal year end, then the latest quarter end: closing price × shares outstanding.

Show table
Bristol-Myers Squibb market cap, annual
PeriodMarket cap
FY2016, ended Dec 31, 2016$97.8B
FY2017, ended Dec 31, 2017$100B
FY2018, ended Dec 31, 2018$84.9B
FY2019, ended Dec 31, 2019$145B
FY2020, ended Dec 31, 2020$139B
FY2021, ended Dec 31, 2021$136B
FY2022, ended Dec 31, 2022$151B
FY2023, ended Dec 31, 2023$104B
FY2024, ended Dec 31, 2024$115B
FY2025, ended Dec 31, 2025$110B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$118B

Revenue

By fiscal year, then the trailing 12 months

Show table
Bristol-Myers Squibb revenue, annual
PeriodRevenue
FY2016, ended Dec 31, 2016$19.4B
FY2017, ended Dec 31, 2017$20.8B
FY2018, ended Dec 31, 2018$22.6B
FY2019, ended Dec 31, 2019$26.1B
FY2020, ended Dec 31, 2020$42.5B
FY2021, ended Dec 31, 2021$46.4B
FY2022, ended Dec 31, 2022$46.2B
FY2023, ended Dec 31, 2023$45.0B
FY2024, ended Dec 31, 2024$48.3B
FY2025, ended Dec 31, 2025$48.2B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$49.2B

Net income and free cash flow

By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.

Show table
Bristol-Myers Squibb net income and free cash flow, annual
PeriodNet incomeFree cash flow
FY2016, ended Dec 31, 2016$4.46B$1.84B
FY2017, ended Dec 31, 2017$1.01B$4.22B
FY2018, ended Dec 31, 2018$4.92B$6.12B
FY2019, ended Dec 31, 2019$3.44B$7.37B
FY2020, ended Dec 31, 2020−$9.02B$13.3B
FY2021, ended Dec 31, 2021$6.99B$15.2B
FY2022, ended Dec 31, 2022$6.33B$11.9B
FY2023, ended Dec 31, 2023$8.03B$12.7B
FY2024, ended Dec 31, 2024−$8.95B$13.9B
FY2025, ended Dec 31, 2025$7.05B$12.8B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$9.28B$11.4B

Cash and cash equivalents

At each fiscal year end, then the latest quarter end.

Show table
Bristol-Myers Squibb cash and cash equivalents, annual
PeriodCash and cash equivalents
FY2016, ended Dec 31, 2016$4.24B
FY2017, ended Dec 31, 2017$5.42B
FY2018, ended Dec 31, 2018$6.91B
FY2019, ended Dec 31, 2019$12.3B
FY2020, ended Dec 31, 2020$14.5B
FY2021, ended Dec 31, 2021$14.0B
FY2022, ended Dec 31, 2022$9.12B
FY2023, ended Dec 31, 2023$11.5B
FY2024, ended Dec 31, 2024$10.3B
FY2025, ended Dec 31, 2025$10.2B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$8.72B

Total debt

At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.

Show table
Bristol-Myers Squibb total debt, annual
PeriodTotal debt
FY2016, ended Dec 31, 2016$6.71B
FY2017, ended Dec 31, 2017$7.96B
FY2018, ended Dec 31, 2018$8.60B
FY2019, ended Dec 31, 2019$49.5B
FY2020, ended Dec 31, 2020$52.7B
FY2021, ended Dec 31, 2021$49.3B
FY2022, ended Dec 31, 2022$43.2B
FY2023, ended Dec 31, 2023$42.6B
FY2024, ended Dec 31, 2024$51.5B
FY2025, ended Dec 31, 2025$47.1B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)$43.9B

Shares outstanding

At each fiscal year end, then the latest quarter end, adjusted for splits. Up 22.1% since FY16.

Show table
Bristol-Myers Squibb shares outstanding, annual
PeriodShares outstanding
FY2016, ended Dec 31, 20161.67B
FY2017, ended Dec 31, 20171.63B
FY2018, ended Dec 31, 20181.63B
FY2019, ended Dec 31, 20192.26B
FY2020, ended Dec 31, 20202.24B
FY2021, ended Dec 31, 20212.18B
FY2022, ended Dec 31, 20222.10B
FY2023, ended Dec 31, 20232.02B
FY2024, ended Dec 31, 20242.03B
FY2025, ended Dec 31, 20252.04B
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)2.04B

Buybacks and new shares

By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.

Show table
Bristol-Myers Squibb share buybacks and issuance, annual
PeriodBought backPaid to employees
FY2016, ended Dec 31, 2016$231M$205M
FY2017, ended Dec 31, 2017$2.47B$199M
FY2018, ended Dec 31, 2018$320M$221M
FY2019, ended Dec 31, 2019$7.30B$441M
FY2020, ended Dec 31, 2020$1.55B$779M
FY2021, ended Dec 31, 2021$6.29B$583M
FY2022, ended Dec 31, 2022$8.00B$457M
FY2023, ended Dec 31, 2023$5.16B$518M
FY2024, ended Dec 31, 2024$0$507M
FY2025, ended Dec 31, 2025$0$553M
Trailing 12 months to Jun 30, 2026 (through Q2 FY2026)—$553M